Last reviewed · How we verify
Arotinolol Hydrochloride
Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure.
Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Arotinolol Hydrochloride |
|---|---|
| Also known as | Almarl |
| Sponsor | Sumitomo Pharma (Suzhou) Co., Ltd. |
| Drug class | Alpha-beta blocker |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a combined alpha and beta-blocker, arotinolol inhibits both beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors. This dual action reduces cardiac contractility and heart rate (beta effects) while also causing vasodilation (alpha effects), resulting in decreased blood pressure and reduced cardiac workload. It is used primarily in the treatment of hypertension and angina pectoris.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Headache
Key clinical trials
- Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension (NA)
- Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate (PHASE4)
- Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arotinolol Hydrochloride CI brief — competitive landscape report
- Arotinolol Hydrochloride updates RSS · CI watch RSS
- Sumitomo Pharma (Suzhou) Co., Ltd. portfolio CI